Common use of Research Programs Clause in Contracts

Research Programs. Subject to and in accordance with the terms of this Agreement, during the Research Term, Isis and Biogen Idec will conduct two research programs, each under a separate mutually agreed plan. The first research program will cover research focused on enhancing the Parties’ knowledge of ASO pharmacokinetics and pharmacodynamics in the central and peripheral nervous systems (such program, the “Core Research Program” and the plan for such program, the “Core Research Plan”). The second research program will focus on the identification and validation of High Interest Targets, and the identification of ALS Targets, that are eligible to become Collaboration Targets (such program, the “Neurological Disease Research Program” and the plan for such program, the “Neurological Disease Research Plan”). Drafts of the Core Research Plan and the initial Neurological Disease Research Plan have been mutually agreed upon by the Parties in writing on or prior to the Effective Date. The Parties will finalize these initially agreed draft plans within [***] days after the Effective Date. Thereafter, the Parties will update such plans at least once before the beginning of each Calendar Year, and submit them to the Neurology JRC for its review and approval. Each update to the Neurological Disease Research Plan will include, at a minimum (i) the activities to support Target Sanction in the Calendar Year covered by such Neurological Disease Research Plan, (ii) any Neurological Disease research to support Collaboration Programs, and (iii) any ongoing work on High Interest Targets from prior Calendar Years. Notwithstanding the foregoing, neither Party will be required to complete any activities under the Core Research Plan or Neurological Disease Research Plan if such Party in good faith believes that such activities are not technically feasible given the then-current state of the art.

Research Programs. Subject to and in accordance with the terms of this Agreement, during the Research Term, Isis Ionis and Biogen Idec will conduct two research programs, each under a separate mutually agreed plan. The first research program will cover research focused on enhancing the Parties’ knowledge of ASO pharmacokinetics and pharmacodynamics in the central and peripheral nervous systems (such program, the “Core Research Program” and the plan for such program, the “Core Research Plan”). The second research program will focus on the identification and validation of High Interest Targets, and the identification of ALS Targets, that are eligible to become Collaboration Targets (such program, the “Neurological Disease Research Program” and the plan for such program, the “Neurological Disease Research Plan”). Drafts of the Core Research Plan and the initial Neurological Disease Research Plan have been mutually agreed upon by the Parties in writing on or prior to the Effective Date. The Parties will finalize these initially agreed draft plans within [***] days after the Effective Date. Thereafter, the Parties will update such plans at least once before the beginning of each Calendar Year, and submit them to the Neurology JRC for its review and approval. Each update to the Neurological Disease Research Plan will include, at a minimum (i) the activities to support Target Sanction in the Calendar Year covered by such Neurological Disease Research Plan, (ii) any Neurological Disease research to support Collaboration Programs, and (iii) any ongoing work on High Interest Targets from prior Calendar Years. Notwithstanding the foregoing, neither Party will be required to complete any activities under the Core Research Plan or Neurological Disease Research Plan if such Party in good faith believes that such activities are not technically feasible given the then-current state of the art.

Research Programs. Subject to and in accordance with the terms of this Agreement, during the Research Term, Isis Ionis and Biogen Idec will conduct two research programs, each under a separate mutually agreed plan. The first research program will cover research focused on enhancing the Parties’ knowledge of ASO pharmacokinetics and pharmacodynamics in the central and peripheral nervous systems (such program, the “Core Research Program” and the plan for such program, the “Core Research Plan”). The second research program will focus on the identification and validation of High Interest Targets, and the identification of ALS Targets, that are eligible to become Collaboration Targets (such program, the “Neurological Disease Research Program” and the plan for such program, the “Neurological Disease Research Plan”). Drafts of the Core Research Plan and the initial Neurological Disease Research Plan have been mutually agreed upon by the Parties in writing on or prior to the Effective Date. The Parties will finalize these initially agreed draft plans within [***] days after the Effective Date. Thereafter, the Parties will update such plans at least once before the beginning of each Calendar Year, and submit them to the Neurology JRC for its review and approval. Each update to the Neurological Disease Research Plan will include, at a minimum (ia) the activities to support Target Sanction in the Calendar Year covered by such Neurological Disease Research Plan, (iib) any Neurological Disease research to support Collaboration Programs, and (iiic) any ongoing work on High Interest Targets from prior Calendar Years. Notwithstanding the foregoing, neither Party will be required to complete any activities under the Core Research Plan or Neurological Disease Research Plan if such Party in good faith believes that such activities are not technically feasible given the then-current state of the art.

Research Programs. Subject to and in accordance with the terms of this Agreement, during the Research Term, Isis Ionis and Biogen Idec will conduct two research programs, each under a separate mutually agreed plan. The first research program will cover research focused on enhancing the Parties’ knowledge of ASO pharmacokinetics and pharmacodynamics the use of ASOs in the central and peripheral nervous systems systems, and the eye and the ear, including with respect to pharmacokinetics and pharmacodynamics, [***] of ASOs (such program, the “Core Research Program” and the plan for such program, the “Core Research Plan”). A draft of the Core Research Plan has been mutually agreed upon by the Parties in writing on or prior to the Effective Date. The second research program will focus on the identification and validation of Strategies directed to High Interest Targets, and the identification of ALS Targets, that which Strategies are eligible to become Collaboration Programs and which High Interest Targets, upon designation of one or more Strategies as Collaboration Programs, will become Collaboration Targets (such program, the “Neurological Disease Research Program” and the plan for such program, the “Neurological Disease Research Plan”). Drafts of the Core Research Plan and the initial Neurological Disease Research Plan have been mutually agreed upon by the Parties in writing on or prior to the Effective Date. The Parties will finalize these initially agreed draft plans within [***] days after the Effective Date. Thereafter, the Parties will update such plans at least once before the beginning of each Calendar Year, and submit them to the Neurology JRC for its review and approval. Each update to the Neurological Disease Research Plan will include, at a minimum (i) itself be comprised of individual plans that set forth the target validation activities to support be conducted by the Parties in order to achieve Target Sanction in the Calendar Year covered by such Neurological Disease Research Plan, (ii) any Neurological Disease research for each Strategy directed to support Collaboration Programs, and (iii) any ongoing work on a High Interest Targets from prior Calendar YearsTarget designated for such activities under Section 1.2.3(d) (each such individual plan for each Strategy, a “Target Sanction Plan”). Notwithstanding the foregoing, neither Party will be required to complete any activities under the Core Research Plan or Neurological Disease Research Plan (or any individual Target Sanction Plan included therein) if such Party in good faith believes that such activities are not technically feasible given the then-current state of the art.